Zidebactam sodium salt
Based on 11 publication(s) in Google Scholar
Zidebactam sodium salt (WCK-5107 sodium salt) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1706777-46-9
- 分子式: C13H20N5NaO7S
- 分子量:413.38
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Zidebactam sodium salt
More- NPJ Antimicrob Resist. 2026 Jul 11.
- Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
- Sci Rep. 2025 Sep 29;15(1):33616. [Abstract]
- Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524. [Abstract]
- Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. [Abstract]
- Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0167621. [Abstract]
- J Antimicrob Chemother. 2025 Apr 2;80(4):1137-1140. [Abstract]
- J Antimicrob Chemother. 2023 May 3;78(5):1191-1194. [Abstract]
- Microbiol Spectr. 2022 Feb 23;10(1):e0267821. [Abstract]
- University of Skovde. 2025.
- bioRxiv. 2025 January 21.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
Beta-lactamase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
IC50: 0.26±0.06 μg/mL (P. aeruginosa PAO1 PBP2)[2].
体外実験
Zidebactam sodium salt (WCK-5107 sodium salt) inhibits WT Enterobacteriaceae with a MIC50 of 0.25 mg/L[1].Zidebactam sodium salt (WCK-5107 sodium salt) alone exhibits variable activity when tested against E. coli (MIC50/90 0.12/0.12 mg/L) and Enterobacter spp. (MIC50/90 0.12/0.25 mg/L)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 1706777-46-9
-
分子量 413.38
-
分子式 C13H20N5NaO7S
-
SMILES
O=C([C@@H]1CCCNC1)NNC([C@@H]2CC[C@@H]3C[N@]2C(N3OS(=O)(O[Na])=O)=O)=O
-
別名
WCK-5107 sodium salt
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
-
Antibiotics (Basel)
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]2021 Nov 3;10(11):1341. PMID: 34827279
Zidebactam sodium salt purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
time–kill curves of Zidebactam (ZID) (0.5 µg/mL; 24 h) on C. amalonaticus N18 and K. pneumoniae KL 12 SG.
-
Sci Rep
Sporadic cefiderocol resistance in Escherichia coli from the United Arab Emirates involves multifactorial mechanisms reversible by novel beta-lactamase inhibitors. [Abstract]2025 Sep 29;15(1):33616. PMID: 41023121
Zidebactam sodium salt purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Sep 29;15(1):33616. [Abstract]
Zidebactam (0.125-0.5 µg/mL) had a potent antibacterial effect on four E. coli strains.
-
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Antimicrob Agents Chemother
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]2023 Jul 18;67(7):e0033923. PMID: 37255469 -
Antimicrob Agents Chemother
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales. [Abstract]2022 Feb 15;66(2):e0167621. PMID: 34807754 -
J Antimicrob Chemother
Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2. [Abstract]2025 Apr 2;80(4):1137-1140. PMID: 39960091 -
J Antimicrob Chemother
In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. [Abstract]2023 May 3;78(5):1191-1194. PMID: 36921067 -
Microbiol Spectr
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate. [Abstract]2022 Feb 23;10(1):e0267821. PMID: 35196805 -
-
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
純度とドキュメンテーション
参考文献
[1]. Sader HS, et al. WCK 5222 ( cefepime/zidebactam ) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases. J Antimicrob Chemother. 2017 Jun 1;72(6):1696-1703. [Content Brief]
[2]. Moya B, et al. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother. 2017 May 24;61(6). [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Zidebactam sodium salt 関連分類
HY-120859A 関連分類
Powered by Bioz